# Tirzepatide: FDA-Approved Dual GIP/GLP-1 Agonist — Regulatory Record and Trial Evidence > Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes, obesity, and obstructive sleep apnea. Independent digest of the SURPASS and SURMOUNT trial record, cited to source. An independent reading desk for the tirzepatide regulatory record. What it is approved to treat, what the SURPASS and SURMOUNT programmes measured, and where the evidence is still incomplete — cited throughout to primary sources. ## The short version Tirzepatide is a prescription medicine approved by the U.S. FDA. It is a synthetic peptide that mimics two gut hormones your body already makes — GIP and GLP-1 — that signal to the pancreas to release insulin after meals. By activating both of these hormone receptors, tirzepatide lowers blood sugar, reduces appetite, and slows digestion. That combination is why it is approved for three different conditions: type 2 diabetes (approved May 2022), chronic weight management in people with obesity or overweight plus a weight-related condition (approved November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity. In clinical trials, it produced the largest weight reductions measured in any large pharmaceutical trial for obesity — up to 20.9% body weight loss at the highest dose over 72 weeks [3]. The most common side effects are nausea, vomiting, diarrhea, and constipation, which are most frequent during dose escalation and usually ease over time. What people report — including the downsides — is on [the effects page](/effects). ## What the Tirzepatide regulatory record shows Tirzepatide (INN: tirzepatide; development code LY3298176) received U.S. FDA approval for type 2 diabetes mellitus in May 2022, making it the first approved dual incretin agonist [7]. A second approval for chronic weight management followed in November 2023. The compound is a 39-amino-acid synthetic peptide based on the native GIP hormone sequence, modified with a C20 fatty diacid moiety that confers albumin-binding affinity and an elimination half-life of approximately five days — the pharmacokinetic basis for once-weekly subcutaneous dosing [10]. The approved subcutaneous formulation is initiated at 2.5 mg once weekly and titrated in 2.5 mg increments every four weeks, with maintenance doses of 5 mg, 10 mg, or 15 mg in the clinical trial programme [7]. The label carries a boxed warning regarding thyroid C-cell tumours observed in rodent carcinogenicity studies; the clinical significance in humans is not established, but the drug is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [7]. This site is an independent editorial digest. It does not sell tirzepatide, does not provide prescriptions, and does not constitute medical advice. It documents the published clinical trial record and regulatory history. ## Tirzepatide weight loss — the SURMOUNT trial results SURMOUNT-1, a 72-week phase 3 randomised controlled trial in 2,539 adults with obesity or overweight plus a weight-related complication and without diabetes, produced mean weight changes of -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg once weekly, versus -3.1% with placebo [3]. Gastrointestinal adverse events were the most common side effects and occurred primarily during dose escalation. SURMOUNT-5, a 72-week head-to-head phase 3b open-label trial in 751 adults with obesity but without type 2 diabetes, compared tirzepatide to the maximum tolerated dose of semaglutide. The least-squares mean weight change at week 72 was -20.2% with tirzepatide versus -13.7% with semaglutide (P<0.001), with tirzepatide also producing a greater reduction in waist circumference and higher proportions achieving ≥10%, ≥15%, ≥20%, and ≥25% weight loss [4]. In [Tirzepatide research](/research) and on the dedicated [what is tirzepatide](/what-is-tirzepatide) page, the mechanism underlying this efficacy — dual GIP and GLP-1 receptor engagement — is examined in detail. ## Tirzepatide vs semaglutide — what the head-to-head trials measured SURPASS-2, a 40-week open-label phase 3 trial in 1,879 adults with type 2 diabetes, compared tirzepatide 5, 10, and 15 mg once weekly against semaglutide 1 mg once weekly. Tirzepatide reduced HbA1c — glycated haemoglobin, the standard blood-sugar control marker — by 2.01, 2.24, and 2.30 percentage points at the three doses versus 1.86 percentage points with semaglutide, with tirzepatide non-inferior and superior at all three doses. Body weight reductions were greater with tirzepatide at all doses, with treatment differences of -1.9, -3.6, and -5.5 kg [2]. SURMOUNT-5 then extended this comparison to the obesity indication, with tirzepatide at its maximum tolerated dose producing -20.2% versus -13.7% weight change with semaglutide at its maximum tolerated dose over 72 weeks, a statistically significant superiority [4]. The 2026 American College of Physicians living clinical guideline placed both semaglutide and tirzepatide as conditional first-line recommendations for obesity, citing the evidence base and noting the need for shared decision-making on benefits, harms, and access [11]. ## Tirzepatide peptide structure and pharmacology Tirzepatide is a tirzepatide peptide of 39 amino acids. Its backbone is derived from the native GIP (glucose-dependent insulinotropic polypeptide) hormone sequence, with strategic substitutions that enable dual receptor engagement. The fatty diacid arm — a C20 eicosanedioic acid moiety attached via a glutamic acid linker and two AEEA spacer units to a lysine side chain — confers high albumin affinity, yielding the approximately five-day elimination half-life that supports once-weekly dosing [10]. In vitro characterisation established that tirzepatide is an imbalanced dual agonist: it engages the GIP receptor (GIPR) to a greater degree than the GLP-1 receptor (GLP-1R), and its GLP-1R engagement exhibits biased signalling that favours cyclic AMP (cAMP) generation over beta-arrestin recruitment [5]. This pharmacological profile — preferential GIPR engagement with biased GLP-1R cAMP signalling — distinguishes tirzepatide from selective GLP-1 receptor agonists and is proposed to contribute to its larger metabolic effects in trials. [Tirzepatide references](/references) includes the full citation list for the structural and mechanistic literature. ## Tirzepatide reviews — patient experience and reported outcomes Tirzepatide reviews in structured patient interviews and post-market reports describe a consistent pattern: appetite markedly suppressed, significant weight reduction, and most gastrointestinal side effects concentrated in the first weeks of each dose escalation. In exit interviews from the SURMOUNT clinical trials, 79–91% of participants described reduced appetite as a top benefit. Structured surveys have documented energy improvements in 62–79% of respondents and mood improvements in approximately 47–55%. The complete account of what participants have reported — both benefits and adverse effects, clearly labelled as anecdotal — is on the [Tirzepatide effects](/effects) page. Clinical trial results provide the controlled evidence; patient-reported outcomes and community observations provide a different layer of context. This site presents both, with clear labels distinguishing the two. ## Tirzepatide results — the scope of the clinical programme Beyond the SURPASS (type 2 diabetes) and SURMOUNT (obesity) programmes, tirzepatide's clinical development has expanded to heart failure with preserved ejection fraction (SUMMIT trial), metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH trial), and obstructive sleep apnea (SURMOUNT-OSA). The 2026 Lancet review of incretin therapies confirms trial-established benefits including prevention of type 2 diabetes progression, MACE risk reduction, HFpEF outcomes, steatotic liver disease fibrosis prevention, and symptomatic sleep apnea improvement [12]. The breadth of the tirzepatide results across metabolic organ systems reflects the downstream effects of coordinated GIP and GLP-1 receptor agonism. A 2026 living systematic review for the ACP found that, across 69 studies and 112,511 participants, semaglutide and tirzepatide produced the greatest weight loss among studied pharmacological interventions, though for tirzepatide specifically the evidence on mortality and major cardiovascular events remains more limited than for semaglutide [11]. --- An independent regulatory reading desk — the tirzepatide approval and trial record, cited to source, with no clinical role held.